A convenient five-drug cocktail for the assessment of major drug metabolizing enzymes:: a pilot study

被引:39
作者
Sharma, A
Pilote, S
Bélanger, PM
Arsenault, M
Hamelin, BA
机构
[1] Laval Hosp, Quebec Heart & Lung Inst, Quebec City, PQ, Canada
[2] Univ Laval, Fac Pharm, Quebec City, PQ, Canada
关键词
caffeine; chlorzoxazone; cocktail; CYP1A2; CYP2C9; CYP2D6; CYP2E1; CYP3A4; cytochrome P450s; dapsone; metoprolol; N-acetyltransferase; tolbutamide;
D O I
10.1111/j.1365-2125.2004.02162.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aims To assess the feasibility of administering at the same time low doses of five probe drugs, metoprolol (25 mg), chlorzoxazone (250 mg), tolbutamide (250 mg), dapsone (100 mg) and caffeine (100 mg) to determine simultaneously the activities of CYP2D6, CYP2E1, CYP2C9, CYP3A4, CYP1A2, N-acetyltransferase-2 and xanthine oxidase. Methods Ten healthy young non-smoking males received the following drugs or combinations of drugs over a 5-week period: week 1) metoprolol; 2) tolbutamide; 3) caffeine, chlorzoxazone and dapsone; 4) caffeine, chlorzoxazone, dapsone and metoprolol; 5) caffeine, chlorzoxazone, dapsone, metoprolol and tolbutamide. The drugs were self-administered at bedtime and urine was collected for the following 8 h. Results Mean molar phenotypic ratios obtained after administering metoprolol (mean change of -11%) or tolbutamide (mean change of -0.3%) alone, were not significantly different from those obtained when other drugs were co-administered (P > 0.05). The mean within-subject coefficients of variation were 33%, 18%, 22%, 13%, 16%, 13% and 5% for CYP3A4, CYP2D6, CYP2C9, CYP2E1, CYP1A2, N-acetyltransferase 2 and xanthine oxidase metabolic ratios, respectively. No significant interactions (P > 0.5) were observed during the simultaneous administration of various combinations of the five probe drugs. Conclusions We propose that this cocktail, composed of five widely available drugs, constitutes a promising means of simultaneously determining the activities of the major CYP enzymes in large populations.
引用
收藏
页码:288 / 297
页数:10
相关论文
共 54 条
[1]   Chloroquine modulation of specific metabolizing enzymes activities: investigation with selective five drug cocktail [J].
Adedoyin, A ;
Frye, RF ;
Mauro, K ;
Branch, RA .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 46 (03) :215-219
[2]   Distribution of mirtazapine (Remeron®) in thirteen postmortem cases [J].
Anderson, DT ;
Fritz, KL ;
Muto, JJ .
JOURNAL OF ANALYTICAL TOXICOLOGY, 1999, 23 (06) :544-548
[3]   INTERACTION BETWEEN 2 PROBES USED FOR PHENOTYPING CYTOCHROMES P4501A2 (CAFFEINE) AND P4502E1 (CHLORZOXAZONE) IN HUMANS [J].
BERTHOU, F ;
GOASDUFF, T ;
LUCAS, D ;
DREANO, Y ;
LEBOT, MH ;
MENEZ, JF .
PHARMACOGENETICS, 1995, 5 (02) :72-79
[4]   EXTREMELY RAPID HYDROXYLATION OF DEBRISOQUINE - A CASE-REPORT WITH IMPLICATION FOR TREATMENT WITH NORTRIPTYLINE AND OTHER TRICYCLIC ANTIDEPRESSANTS [J].
BERTILSSON, L ;
ABERGWISTEDT, A ;
GUSTAFSSON, LL ;
NORDIN, C .
THERAPEUTIC DRUG MONITORING, 1985, 7 (04) :478-480
[5]   Combined phenotypic assessment of cytochrome P450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the "Cooperstown 5+1 cocktail" [J].
Chainuvati, S ;
Nafziger, AN ;
Leeder, JS ;
Gaedigk, A ;
Kearns, GL ;
Sellers, E ;
Zhang, YH ;
Kashuba, ADM ;
Rowland, E ;
Bertino, JS .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 74 (05) :437-447
[6]   The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: Screening costs and influence on clinical outcomes in psychiatry [J].
Chen, SQ ;
Chou, WH ;
Blouin, RA ;
Mao, ZP ;
Humphries, LL ;
Meek, C ;
Neill, JR ;
Martin, WL ;
Hays, LR ;
Wedlund, PJ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1996, 60 (05) :522-534
[7]   URINARY-EXCRETION OF 6-HYDROXYCHLORZOXAZONE AS AN INDEX OF CYP2E1 ACTIVITY [J].
DREISBACH, AW ;
FERENCZ, N ;
HOPKINS, NE ;
FUENTES, MG ;
REGE, AB ;
GEORGE, WJ ;
LERTORA, JJL .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 58 (05) :498-505
[8]   A pharmacophore for human pregnane X receptor ligands [J].
Ekins, S ;
Erickson, JA .
DRUG METABOLISM AND DISPOSITION, 2002, 30 (01) :96-99
[9]  
FLEMING CM, 1992, MOL PHARMACOL, V41, P975
[10]   Determination of chlorzoxazone and 6-hydroxychlorzoxazone in human plasma and urine by high-performance liquid chromatography [J].
Frye, RF ;
Stiff, DD .
JOURNAL OF CHROMATOGRAPHY B-BIOMEDICAL APPLICATIONS, 1996, 686 (02) :291-296